Pre-surgery targeted drugs for selected colorectal cancer tumors
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests targeted cancer drugs given before planned colon or rectal surgery. It may help by trying to shrink the tumor and treat specific tumor “targets” found in your stored pathology sample, depending on your tumor’s genetics and marker tests.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You can sign consent and you’re at least 18 years old.
- Your colon/rectal cancer is confirmed as adenocarcinoma and is judged operable with surgery aiming to fully remove it (R0 margins).
- Your scans show no distant spread (no metastases on CT chest/abdomen/pelvis).
- You have no need for pre-surgery radiation/chemoradiation for rectal cancer (based on the study team).
- Your tumor sample already available from diagnosis (FFPE tissue) is enough for genetic/molecular testing, and you match one of the study’s molecular groups.
- You have good blood counts and organ function (bone marrow, kidney, and liver), and your heart pumping strength is high enough where required; you also must not be pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of treatments before surgery for locally advanced rectal cancer. You would receive short-course radiation, then an immunotherapy drug (camrelizumab) plus a PARP inhibitor (fluzoparib) and chemotherapy, to shrink the tumor and make surgery more successful.
This trial tests a combination of chemotherapy and a targeted drug (fruquintinib) given before surgery to shrink colorectal cancer. It aims to see if this approach helps make tumors easier to remove or even disappear, especially for patients whose cancer has spread a little or is in a tricky spot.
This trial tests a combination of chemotherapy, an immunotherapy drug (anti-PD-1 antibody), and sitagliptin before surgery for colorectal cancer that has not spread to other organs. The goal is to see if this approach can shrink the tumor and improve outcomes.
This Phase 2 trial tests whether a newer combination chemotherapy plus an immunotherapy medicine (cadonilimab/AK104) works better than standard chemotherapy before surgery for locally advanced colorectal cancer. The goal is to shrink the tumor and improve how well treatment works after surgery.
This trial tests two new drugs (fruquintinib and tislelizumab) plus standard chemo before surgery for rectal cancer that has not spread. The goal is to see if this combination works better than standard chemo alone.
This trial tests whether giving chemotherapy before surgery can improve outcomes for people with colon cancer that has grown into nearby tissue or lymph nodes but hasn't spread to other organs. It is for patients whose tumors are mismatch repair proficient (pMMR) or microsatellite stable (MSS).
Hear when a new Colorectal cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.